ESR1 and breast carcinoma: Postmenopausal patients with primary, estrogen receptor-positive (ER+) breast cancer were randomized to several weeks of tamoxifen, anastrozole, or fulvestrant prior to routine surgery, while all premenopausal patients received tamoxifen by default.